Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab

This publication has 32 references indexed in Scilit:

• Combined Chemotherapy-Immunotherapy for Advanced Biliary Tract Cancer (BTC): A Clinical, Genomic, and Biomarker Analysis
  Journal of Gastrointestinal Cancer, 2025
• ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer
  ESMO Open, 2024
• Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab
  Targeted Oncology, 2024
• Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
  The Lancet, 2023
• Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma
  Journal of Hepatology, 2022
• Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
  Annals of Oncology, 2022
• Biomarkers for response to immunotherapy in hepatobiliary malignancies
  Hepatobiliary & Pancreatic Diseases International, 2022
• Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma
  European Journal of Cancer, 2022
• Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers
  ESMO Open, 2021
• Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma
  Journal of Hepatology, 2019